Skip to main content
Fig. 1 | Health Economics Review

Fig. 1

From: The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China

Fig. 1

Scatter plots of the incremental cost-effectiveness ratios for once-weekly semaglutide 0.5 mg + metformin versus sitagliptin + metformin (a) and once-weekly semaglutide 1 mg + metformin versus sitagliptin + metformin (b) with a cost-effective threshold value of ¥85,698 ($12,720) (one time GDP per capita of China in 2022)

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us